Skip to main content
. 2018 May 2;8(10):e1078062. doi: 10.1080/2162402X.2015.1078062

Figure 1.

Figure 1.

The effect of CD4+ Th1 cytokines (IFNγ/TNFα) and HER2 targeted monoclonal antibodies (Trastuzumab/Pertuzumab) on MHC class-I expression and CD8+ T-cell mediated cytotoxicity in SK-BR-3 cells (E:T = 10:1). Both HLA-A2 MHC class I expression and CD8+ cytotoxicity remained low following treatment with Trastuzumab alone (96.4 ± 70.6 MCF, 11.7%), Pertuzumab alone (103.4 ± 81.6 MCF, 9.7%), and Trastuzumab/Pertuzumab (113.8 ± 83.2 MCF, 11.5%), at levels similar to MHC class I expression without treatment (87.1 ± 64.9 MCF, 9.5%). HLA-A2 MHC class-I expression and CD8+ cytotoxicity both increased following treatment with IFNγ/TNFα (386.6 ± 171.4 MCF, 20.4%), IFNγ/TNFα and Trastuzumab (512.9 ± 95.1 MCF, 28.9%), IFNγ/TNFα and Pertuzumab (486.3 ± 166.7 MCF, 28.6%), with the greatest increase following treatment with IFNγ/TNFα and Trastuzumab/Pertuzumab (813.3 ± 117.8 MCF, 34.6%).